Jan Štraub

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 834 citations · Full text

Hematological Malignancy, Oncology, Dexamethasone Versus Bortezomib +8

The Effect of Oral Omeprazole on Gastric Acid and Pepsin Secretion

H.P.M. Festen, J. Défize, Rune R. Frants et al. · Scandinavian Journal of Gastroenterology · 1986 · 48 citations

Gastrointestinal Peptide Hormone, Pepsin Secretion, Biochemistry +10

Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy

Jiří Minařík, Petr Pavlíček, Luděk Pour et al. · PLoS ONE · 2015 · 37 citations · Full text

Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure

Lukáš Lambert, Petr Ouředníček, Zuzana Mecková et al. · Oncology Letters · 2017 · 37 citations · Full text

Computed Tomography, Fracture Diagnostics, Comparable Radiation Dose +25

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Jiří Minařík, Tomáš Pika, Jakub Radocha et al. · BMC Cancer · 2021 · 33 citations · Full text